10 Weekend Reads
The weekend is here! Pour yourself a mug of Danish Blend coffee, grab a seat outside, and get ready for our longer-form weekend reads: • In the Shadow of Jane Street and Citadel Securities, Hudson River Mints Billions: The quiet flash boy has morphed into a powerhouse among non-bank market makers. (Bloomberg free) • In every corner […]
Chicago food companies like Mush, Farmer’s Fridge flourish as consumers move away from processed foods
A decade ago, Ashley Thompson created the ready-to-eat overnight oats company Mush — a brand that bills itself as a healthier breakfast with nutrient-dense ingredients, free of fillers and additives. The Chicago-based company has sold more than 200 million cups, and its appeal among shoppers caught the attention of its retail partner Whole Foods, who […]
GLP-1 Weight Loss Drugs Have an Unexpected Side Effect
Ed Cara, Gizmodo Every drug has its risks, no matter how tremendous its benefits may be, and sometimes it can take a while to uncover less obvious side effects. New research suggests that…
Food Exec Brief: AI Velocity, GLP-1 Disruption, and Manufacturing’s Autonomous Future
Welcome to this week’s Food Exec Brief, your strategic intelligence roundup covering the accelerating deployment of AI across R&D and operations, the seismic impact of GLP-1 medications on consumer behavior, and the convergence of automation and sustainability reshaping competitive dynamics in food and beverage manufacturing. Key takeaways: AI moves from novelty to necessity: Food giants […]
Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves
Tempus AI TEM is slowly becoming one of the most vertically integrated data and diagnostics platforms in healthcare, bringing together genomics, multimodal real-world data and clinical AI into a unified system. As its financial performance improves and more FDA-cleared diagnostic tools enter the portfolio, the company is shifting from a heavy investment phase toward a […]
Ozempic on Cats? Updates on Biopharmaceutical Company Launches Pilot Study of GLP-1 Drug in Obese Cats
An Ozempic-like drug implant might be available for your pets soon. Okava Pharma’s GLP-1 implant pilot for obese cats (MEOW-1) aims to combat feline obesity, with due results in 2026.
Leading Drug Fails to Slow Alzheimer’s Progression
(MedPage Today) — Alzheimer’s patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to…
Weight loss drugs have great action, but can’t replace diet and exercise: Diabetes Federation president
“The new GLP-1 class of drugs comprises brilliant molecules that have very good action, but they are also very expensive”
Scientists Testing GLP-1s for Overweight Dogs and Cats
Your pet dog or cat might soon be a chubby little munchkin no more. Welcome to the burgeoning era of — we swear we’re not making this up — “ozempets,” in which your servile critters might shed some extra pounds by taking animal-focused diabetes and weight loss drugs similar to Ozempic and Wegovy. It hasn’t […]
Why Is Cencora (COR) Down 6.3% Since Last Earnings Report?
A month has gone by since the last earnings report for Cencora (COR). Shares have lost about 6.3% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Cencora due for a breakout? Well, first let’s […]